ALEC
ALEC clinical trials: Alector, Inc.
Every trial on ClinicalTrials.gov where Alector, Inc. is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 12
- Trials linked
- 10
- As lead sponsor
- 2
- As collaborator
- 0
- Primary completions as lead sponsor, next 90 days
ALEC on the catalyst calendar · ALEC registry changes
- Primary completion Sep 1, 2025ActualPhase 3NCT04374136A Phase 3 Study to Evaluate Efficacy and Safety of AL001 in Frontotemporal Dementia (INFRONT-3)Alector Inc. · Frontotemporal DementiaTerminatedALECLeadGSKCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 31, 2025ActualPhase 2NCT05744401A Long-term Extension Study to Evaluate Safety, Tolerability, and Efficacy of AL002 in Alzheimer's DiseaseAlector Inc. · Alzheimer's DiseaseTerminatedALECLeadABBVCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 1, 2025ActualPhase 3NCT06111014Continuation Study for LatozinemabAlector Inc. · Neurodegenerative DiseasesTerminatedALECLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 5, 2024ActualPhase 2NCT03987295A Phase 2 Study to Evaluate Safety of Long-term AL001 Dosing in Frontotemporal Dementia (FTD) Patients (INFRONT-2)Alector Inc. · Frontotemporal DementiaCompletedALECLeadGSKCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 19, 2024ActualPhase 2NCT04592874A Phase 2 Study to Evaluate Efficacy and Safety of AL002 in Participants With Early Alzheimer's DiseaseAlector Inc. · Alzheimer DiseaseCompletedALECLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 28, 2022ActualPhase 2NCT05053035A Phase 2 Study to Evaluate AL001 in C9orf72-Associated ALSAlector Inc. · Amyotrophic Lateral SclerosisTerminatedALECLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 9, 2022ActualPhase 1NCT04111666A Phase 1 First in Human Study to Assess Safety and Tolerability of AL101Alector Inc. · HealthyCompletedALECLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 6, 2021ActualPhase 1NCT03822208First in Human Study for Safety and Tolerability of AL003.Alector Inc. · HealthyCompletedALECLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 3, 2020ActualPhase 1NCT03635047A Phase I Study for Safety and Tolerability of AL002.Alector Inc. · HealthyCompletedALECLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 31, 2019ActualPhase 1NCT03636204A First in Human Study in Healthy Volunteers and in Participants With Frontotemporal Dementia With Granulin (GRN) MutationAlector Inc. · HealthyCompletedALECLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 14, 2026ActualPhase 2NCT06079190Efficacy and Safety of GSK4527226 [AL101] in Participants With Early Alzheimer's DiseaseGlaxoSmithKline · Alzheimer's DiseaseTerminatedGSKLeadALECCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 15, 2028Sponsor estimatePhase 2NCT07105709Open-label Extension Study in Participants With Early Alzheimer's DiseaseGlaxoSmithKline · Alzheimer's DiseaseRecruitingGSKLeadALECCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 12 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScanner